Clinical Trials - February 17, 2014
NeuroVive reaches milestone in European phase III trial on CicloMulsion
The last of a total of 972 patients have now been enrolled and treated in the company’s ongoing European phase III trial (CIRCUS). In the trial, half of patients received the company’s pharmaceutical CicloMulsion for treating reperfusion injury coincident with myocardial infarction. “We’ve now reached a major milestone in the European cardiac study on NeuroVive’s product […]
Clinical Trials - September 11, 2013
800 patients involved in NeuroVive’s Phase III study
NeuroVive has announced that more than 800 patients are to be included in their ongoing European Phase III study with CicloMulsion for treatment of reperfusion injury following a heart attack. The study is going according to the initial plan, says the company, and at the moment there are 44 active centers involved, in France, Belgium […]
Agreement - June 17, 2013
Neurovive and Isomerase enter agreement
Mitochondrial medicine company Neurovive Pharmaceutical recently announced the signing of a collaboration agreement with Isomerase Therapeutics. The agreement involves the product development and commercialization of the cyclophilin-inhibiting molecules that were recently acquired from Biotica Ltd. According to a press release, the collaboration will focus on cellular protection for traumatic brain injury and heart attack, and […]
